From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 3,4-CTMP
Chemical Nomenclature
Common names 3,4-CTMP
Substitutive name 3,4-Dichloromethylphenidate
Systematic name Methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate
Class Membership
Psychoactive class Stimulant
Chemical class Phenidate
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold < 2 mg
Light 2 - 4 mg
Common 4 - 6 mg
Strong 6 - 8 mg
Heavy 8 mg +
Total 6 - 18 hours
Onset 1 - 2 hours
After effects 2 - 24 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


3,4-Dichloromethylphenidate (also known by the incorrectly abbreviated name 3,4-CTMP) is a stimulant substance of the phenidate class. It is a structural analog of methylphenidate (Ritalin). The two substances have similar pharmacological profiles but different subjective effects.

It is approximately seven times more potent than methylphenidate in animal studies[citation needed], but likely has weaker reinforcing effects due to its slower onset of action.[citation needed] According to anecdotal reports, the active dose of 3,4-CTMP is approximately 10 times lower than the dose of methylphenidate to achieve a similar effect. 3,4-CTMP has a duration of 6 to 18 hours rather than the 4 to 6 hour duration found with methylphenidate.

3,4-CTMP has an extremely short history of human recreational use and has yet to be documented being sold on the streets. It is available for sale as grey market research chemical by online vendors.[citation needed]

Due to its potent stimulant effects, habit-forming properties as well as an unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if using with this substance.


3,4-CTMP, or 3,4-dichloromethylphenidate, is a synthetic molecule of the substituted phenethylamine and substituted phenidate classes. It contains a phenethylamine core featuring a phenyl ring bound to an amino -NH2 group through an ethyl chain. It is structurally similar to amphetamine, featuring a substitution at Rα which is incorporated into a piperidine ring ending at the terminal amine of the phenethylamine chain. Additionally, it contains a methyl acetate bound to Rβ of its structure and is chlorinated at R3 and R4 of its phenyl ring.

3,4-CTMP is nearly identical in structure to methylphenidate; the difference is that it contains two chlorine atoms bonded to the phenyl group at the 3 and 4 positions.


Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

3,4-CTMP acts as a dopamine and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of dopamine and norepinephrine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.[1] 3,4-CTMP has also been identified as a relatively potent agonist of 5-HT2B serotonin receptors.[2] This is concerning, as agonism of the 5-HT2B receptors results in a potentially serious effect called pulmonary hypertension, where the pulmonary artery that pumps blood from the heart to the lungs constricts. Additionally, chronic stimulation of 5-HT2B receptors has been implicated in serious heart valve disease via fibrosis. Other drugs with this effect, such as aminorex (a pharmaceutical weight loss drug that was pulled from the market), have resulted in a large number of long term heart injuries and fatalities across the world.

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

After effects
Aftereffects (3).svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational 3,4-CTMP use do not seem to have been studied in any scientific context, and the exact toxic dosage is unknown. This is because 3,4-CTMP is a research chemical with very little history of human usage.

Although anecdotal evidence from people who have tried 3,4-CTMP suggests that there are unlikely to be negative health effects attributed to simply trying the substance by itself at low to moderate doses, the agonist activity it displays for the 5-HT2B receptor is a cause for concern, as acute 5-HT2B agonism has been shown to result in a potentially dangerous and largely asymptomatic effect called pulmonary hypertension.[citation needed] Moreover, the long-term stimulation of 5-HT2B receptors has been shown to lead to fibrosis of the heart valves, which may result in stroke and/or severe, permanent heart disease.[3]

Other substances that display this activity, such as the recalled weight-loss drug aminorex, have caused serious and often fatal heart disease when used for even relatively short periods of time.[citation needed] It is highly recommended that, should one choose to use this substance despite these concerns, it only be taken very sparingly and in low doses. Those with cardiovascular diseases of any kind should not consume this substance. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Extreme caution must be taken when managing one's 3,4-CTMP usage as the duration of its stimulating effects can be very long, which can cause unwanted sleep inhibition. This should be considered when redosing as the physically stimulating effects of a dose may persist after the psychological effects have worn off. A user attempting to maintain a state of euphoria may run the risk of accumulating medically dangerous quantities of the substance in their bloodstream.

It is strongly recommended that one not insufflate 3,4-CTMP as it has a low solubility in water so is not readily absorbed through the nasal mucus membrane and anecdotal reports suggest that insufflation of the substance is painful and potentially extremely caustic.[citation needed] Additionally, the poor adsorption by the nasal mucus membrane often results in the majority of the substance slowly entering the stomach through a post-nasal drip, making the onset duration even longer, which may increase the chance of an 'accidental overdose' if one redoses more due to a lack of effect.

It is strongly recommended that one use harm reduction practices when choosing to use this substance.

Tolerance and addiction potential

In terms of its tolerance, many users have reported that 3,4-CTMP can be used for multiple days in a row for extended periods of time without any noticeable acute tolerance build up, instead increasing gradually over regular and extended use. Unusually, there are some reports indicating a sudden rise in tolerance after an extended period of relatively little increase. This results in the user requiring an increase in dosage to achieve the same effects or to remain functional. Increasing dose to match tolerance places one at high risk of addiction.

It has been reported that 3,4-CTMP has potential for abuse on par with that of amphetamine or MDMA due to its lack of significant tolerance, euphoric effects and action upon dopamine transporters.[citation needed]

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with 3,4-CTMP should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
  • Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
  • MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
  • MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
  • Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
  • Stimulants - 3,4-CTMP may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
  • Tramadol - Tramadol is known to lower the seizure threshold[4] and combinations with stimulants may further increase this risk.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Canada: 3,4-CTMP is a Schedule III controlled substance in Canada.[6]
  • China: As of October 2015 3,4-CTMP is a controlled substance in China.[7]
  • Germany: 3,4-Dichloromethylphenidate is controlled under the NpSG (New Psychoactive Substances Act)[8] as of November 26, 2016.[9] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[10]
  • Japan: 3,4-CTMP is a controlled substance in Japan effective March 6th, 2014.[11]
  • Sweden: 3,4-Dichloromethylphenidate is illegal as of 10 November 2014.[12]
  • Switzerland: 3,4-CTMP is a controlled substance specifically named under Verzeichnis E.[13]
  • Turkey: 3,4-Dichloromethylphenidate is a classed as drug and is illegal to possess, produce, supply, or import.[14]
  • United Kingdom: 3,4-Dichloromethylphenidate is a class B drug in the UK as of 31st May 2017 and is illegal to possess, produce or supply. [15]
  • United States: 3,4-Dichloromethylphenidate is not explicitly controlled in the US, but it could possibly be considered an analog of a Schedule II substance (methylphenidate) under the Federal Analog Act.[citation needed]

See also

External links


  1. Davies, H. M. L., Hopper, D. W., Hansen, T., Liu, Q., Childers, S. R. (April 2004). "Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites". Bioorganic & Medicinal Chemistry Letters. 14 (7): 1799–1802. doi:10.1016/j.bmcl.2003.12.097. ISSN 0960-894X. 
  2. 2.0 2.1 Arunotayanun, W. (2014), Chemical and biological studies on natural and synthetic Novel Psychoactive Substances, University College London (University of London) 
  3. Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., Roth, B. L. (5 December 2000). "Evidence for Possible Involvement of 5-HT 2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications". Circulation. 102 (23): 2836–2841. doi:10.1161/01.CIR.102.23.2836. ISSN 0009-7322. 
  4. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  5. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210Freely accessible. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  6. Consolidated federal laws of Canada, Controlled Drugs and Substances Act, 2022 
  7. http://www.sfda.gov.cn/WS01/CL0056/130753.html | 关于印发《非药用类麻醉药品和精神药品列管办法》的通知
  8. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 23, 2019. 
  9. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 23, 2019. 
  10. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 23, 2019. 
  11. "○平成26年3月6日付けで以下の10物質が指定薬物に指定されました。" (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved May 2, 2022.
  12. Cannabinoider föreslås bli klassade som hälsofarlig var | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/
  13. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  14. https://resmigazete.gov.tr/eskiler/2017/01/20170112-8.pdf
  15. The Misuse of Drugs Act 1971 (Amendment) Order 2017